IntegraDose Compounding Services, LLC, Minneapolis, MN

Is IntegraDose Compounding Services, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B. The list does name IntegraDose Compounding Services, LLC in Shoreview, MN, a close but not exact match shown below.

Does IntegraDose Compounding Services, LLC hold a Minnesota pharmacy license?

State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.

Has IntegraDose Compounding Services, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (May 6, 2020) and 2 FMD-145 letters (Mar 25, 2026 and Mar 26, 2026) for IntegraDose Compounding Services, LLC. State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
IntegraDose Compounding Services, LLC
Location
Minneapolis, MN
Type as FDA labels it
503B
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
1
Latest action on that page
Aug 12, 2026
FDA Data Dashboard inspections
No matching site found
Form 483 text on this page
1 Form 483, 6 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as IntegraDose Compounding Services, LLC, a 503B facility, with 8 dated actions.

Document
Aug 12, 2026Form 483483 Issued 08/12/2026fda.gov
Mar 26, 2026FMD-145 letterFMD-145 Letter Issued 3/26/2026Not linked by FDA
Mar 25, 2026FMD-145 letterFMD-145 Letter Issued 3/25/2026Not linked by FDA
Jul 25, 2025Form 483483 issued 07/25/2025fda.gov
Sep 5, 2024Regulatory meetingRegulatory Meeting Held 09/05/2024Not linked by FDA
Mar 1, 2024Form 483483 Issued 03/01/2024fda.gov
Aug 2, 2021Form 483483 Issued 08/02/2021FDA copy (archived)
May 6, 2020Warning letterWarning Letter (05/06/2020)FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

The dashboard does list IntegraDose Compounding Services LLC, Shoreview, MN (FEI 3014483112): same name and state, different city, so not treated as this site.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 15, 2025 to Jul 25, 2025: 6 observations

Firm on the cover
IntegraDose Compounding Services LLC, 719 Kasota Ave Se, Minneapolis, MN 55414-2842
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
DISTRIC T ADDRESS AND PHONE NUMBER 250 Marquette Ave, Ste. 600 Minneapolis, MN 55401
Matched to this page by
firm name, city and state on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not written and followed.

***Repeat Observation from FDA Inspections ending 09/19/2018, 08/02/2021 , and 03/01/2024***

Specifically,

1) On 7/15/2025, during production of Fentanyl Citrate 2500mcg CADD lot 20250715FEN-l , your production technicians performed the following poor aseptic techniques:

a . Finished product vials of Fentanyl Citrate were uncapped within the ISO-7 area prior to filling vials into a pool bag.

One technician in hood <Redacted B4> was seen throwing CADD cassette tubing caps from inside the ISO-5 hood to a trashcan located outside of the hood in the ISO-7 environment. 4.lJ

b.

2) On 7/15/2025, during production of Oxytocin 30U/500mL bag lot 20250715OXY-2, your production technicians performed the following poor aseptic techniques:

a. One technician in hood <Redacted B4> was seen handling product vials in a manner that blocked first pass air over vials that were being drawn up into a pool bag. The tops of vials were blocked by the technicians gloved hands.

b. ...

Read the full 483 (PDF on fda.gov)

Observation 2

The statistical quality control criteria fail to include appropriate rejection levels.

Specifically,

Your firm's 100% visual inspection reinspection AQL evaluation has an acceptance limit that is greater than the acceptance limits set for initial 100% visual inspection. The reinspection acceptance limit is not scientifically or statistically justified. Your firm released the following batches with critical defects identified during reinspection:

a) Fentanyl Citrate 2500mcg/50mL in sterile water lot 20240911FEN-1, expiry 3/10/2025, had an initial inspection of 11 critical particle defects found during 100% inspection. Your firm opened an investigation and reinspected the lot and found an additional 3 critical particle defects. This is above the limit of 4K critical defects for reinspection for the batch size, per the production batch record. Your firm released this batch.

record. Your fnm released this batch.

b) Cefazolin 3g/30mL lot 20240830CE2-1 , expiry 11/28/2024, had an initial inspection of 4 critical particle defects found during 100% inspection. Your firm opened an investigation and reinspected the lot. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

Specifically,

1) Your firm's visual inspection <Redacted B4> used during qualification is not representative of the visual inspection process. During visual inspection of a production batch only one contains closure system type, size, and product are inspected at a time. Your firm's visual inspection <Redacted B4> contains units of various container closure systems, sizes, products, and defects.

2) Your firm does not have a library of defects from which on the job training <Redacted B4> can be obtained. The only defects available for training are defects within the qualification <Redacted B4>. All defects are not present in the visual inspection qualification <Redacted B4> Defects missing from <Redacted B4> include critical defects such as missing syringe cap, expired bags used for final product, and cracked syringe banels. In addition, particles contained in the qualification <Redacted B4> has critical defects are undefined as to composition, size, and origination (i.e. Extrinsic, Intrinsic, and Inherent). ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

***Repeat observation from FDA inspections ending 08/02/2021 and 03/01/2024***

Specifically,

Dynamic smoke studies were performed utilizing smoke from a combustible source, smoke matches. This smoke has not been evaluated by your firm for use in cleanroom hoods for factors such as sterility of smoke, particle generation, and cleanability of residues. In addition, smoke cannot be visualized in all smoke study videos due to blocked camera angles by personnel and manual application of smoke by personnel.

Observation 5

Specifically,

Your firm does not perform contemporaneous two-person verification of environmental monitoring plates. A single laboratory technician reads environmental plate samples and records the results of the plate counts on a worksheet. There is no assurance that the operator has entered the data accurately.

Observation 6

The quality control unit lacks responsibility to approve all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

***Repeat observation from inspection ending 3/1/2024***

Specifically,

Your firm failed to adequately assess the use of rapid sterility for your products including but not limited to reviewing the validation, reviewing the method for acceptability of use, and reviewing the equivalency testing to USP <71 > for the release of all final products using rapid sterility.

State board of pharmacy records

State board of pharmacy records for Minnesota are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.

Close but not exact matches

These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.